Cyp trading, page-105

Following up on last Thursday's symposium, a bio nikkei affiliate/associate tweeted from the event twice, first tweet was about the opening speech and the second one was about Cynata:



"WM's depression. A lecture by Cynata, Australia, which began clinical trials of iPS cells for the first time in the world, began. Human iPS cells from CDI Inc. are used."

Also, DDNews Pharma, Biotech and Life Science mentioned our second preclinical Asthma study in their latest issue:

"Cymerus MSCs show synergy with dexamethasone

February 2018

MELBOURNE, Australia—Cynata Therapeutics Limited recently announced the receipt of the final report on the effects of Cymerus MSCs in combination with or in comparison to dexamethasone in a preclinical asthma study. Daily administration of the drug resulted in significant anti-inflammatory effects in a mouse model. The corticosteroid reduced airway inflammation by 55 percent and airway inflammation-induced goblet cell metaplasia by roughly 80 percent. It showed only weak anti-remodeling and anti-fibrotic effects, however, and reduced airway hyperresponsiveness by only about 30 percent. Once-weekly dosing of Cymerus MSCs, however, led to marked reductions in airway remodeling, fibrosis and airway hyperresponsiveness (70 to 75 percent). The drug also normalized subepithelial collagen deposition and airway TGF-β1 expression levels equivalent to mice that had not been induced with asthma. Together the treatments demonstrated a synergistic effect that featured the anti-inflammatory effects of dexamethasone alone and the reductions seen with Cymerus MSCs alone."
http://www.ddn-news.com/index.php?newsarticle=12157